Cancer Research · global
Personalized mRNA Cancer Vaccine Reports Phase 3 Success: Risk of Recurrence or Death After Melanoma Surgery Falls 42%
Moderna and Merck announced results from a trial involving more than 1,000 participants, with the vaccine plus Keytruda improving two-year recurrence-free survival by 12.2 percentage points; whether it extends overall survival requires further follow-up.
After melanoma is surgically removed, the next treatment challenge is keeping the cancer from returning. On October 22, Moderna and Merck (MSD) announced Phase 3 trial data showing that adding the personalized mRNA cancer vaccine intismeran autogene to postoperative immunotherapy further reduced the risk of recurrence or death, providing evidence from a large randomized trial for a therapy designed around the characteristics of each patient’s tumor.
The study was one of the focal points of the European Society for Medical Oncology (ESMO) 2026 Congress. A Stocktwits pharmaceutical industry preview published by Yahoo Finance had listed it among the week’s important clinical developments; Merck’s October 13 agenda announcement confirmed that INTerpath-001 would be presented for the first time at a Presidential Symposium in Madrid. The detailed data released afterward shifted the discussion from a conference preview to an assessment of efficacy and risks.
INTerpath-001 enrolled 1,137 patients with stage IIB to IV melanoma whose tumors had been completely resected. The randomized, double-blind trial compared intismeran autogene plus pembrolizumab (brand name Keytruda) with placebo plus pembrolizumab. Both groups received immunotherapy, so the trial tested whether the vaccine could provide additional protection on top of existing treatment.
After a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42%, with a hazard ratio of 0.58 and a 95% confidence interval of 0.45 to 0.75; the risk of distant metastasis or death fell by 38%. Two-year recurrence-free survival rates were 82.2% and 70.0%, respectively, a difference of 12.2 percentage points. This absolute difference and the 42% relative risk reduction offer two different perspectives on efficacy and cannot be used interchangeably.
The design of this investigational vaccine starts with mutations unique to each patient’s tumor. The research team uses DNA information from tumor and normal tissue to select neoantigens, then encodes them in mRNA to prompt the immune system to recognize the relevant cancer cells. Pembrolizumab blocks inhibitory PD-1 signaling to help immune cells function. Together, the two treatments seek to provide both recognition targets and support for the immune response.
Beyond efficacy, the treatment burden on patients after surgery is equally important. Grade 3 to 5 treatment-related adverse events occurred in 14.2% of the combination group and 13.4% of the control group; common adverse events in the combination group included fever, injection-site pain, and fatigue. The similar rates of higher-grade events in the two groups still do not mean the additional course of treatment comes without a burden.
The clearest evidence so far is that the combination improved recurrence-free and distant metastasis-free survival outcomes in this patient population. Overall survival data remain immature, so these findings do not yet establish that patients live longer and cannot be directly extrapolated to other cancer types. Merck said it is engaging with regulatory authorities; moving from Phase 3 results to clinical use still requires review, while longer-term follow-up will determine how long the protection lasts.